Quantcast

Latest Edison Pharmaceuticals Stories

2014-06-05 23:16:50

CEO and founder of Edison Pharmaceuticals has changed the lives of many children and families with mitochondrial disease BOSTON, MA (PRWEB) June 05, 2014 Guy Miller, MD, PhD, CEO and founder of Edison Pharmaceuticals has changed the lives of many children and families with mitochondrial disease. For his efforts, MitoAction recognized him with its “Making a Difference For Mito” award. Dr. Miller was chosen based on his extensive and ongoing contribution to the mitochondrial disease...

2014-05-21 00:20:51

EPI-743 in phase 2B/3 development for Leigh syndrome MOUNTAIN VIEW, Calif., May 21, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome. EPI-743 is currently in phase 2B development for the treatment of Leigh syndrome. A phase 2B randomized double-blind placebo-controlled trial in children with Leigh syndrome is fully enrolled in the...

2014-03-19 23:25:02

EPI-743 gains key regulatory endorsement. Downingtown, PA, (PRWEB) March 19, 2014 Edison Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Status to EPI-743 for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-awards-fast-track-status-to-edison-pharmaceuticals-epi-743-for-friedreichs-ataxia-250558901.html). This status will further accelerate the clinical development of EPI-743 now under way in two...

2014-03-17 00:23:45

EPI-743 in two phase 2 development studies for Friedreich's ataxia MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the United States Food and Drug Administration granted Fast Track designation to EPI-743, the company's lead drug, for the treatment of Friedreich's ataxia. EPI-743 is being developed for pediatric and adult mitochondrial disease, including Friedreich's ataxia. EPI-743 has successfully completed phase 1 and multiple...

2014-03-17 00:23:41

FDA approves IND for clinical trial in ultra rare orphan mitochondrial disease MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone(TM)) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products. The trial is a...

2014-02-04 23:00:35

EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-grants-edison-pharmaceuticals-epi-743-orphan-status-for-friedreichs-ataxia-243439351.html). Orphan status brings additional momentum and acceleration to the...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related